ResMed Inc. (RMD)

NYSE: RMD · IEX Real-Time Price · USD
204.89
+1.00 (0.49%)
Jul 19, 2024, 10:32 AM EDT - Market open
0.49%
Market Cap 30.07B
Revenue (ttm) 4.58B
Net Income (ttm) 958.38M
Shares Out 146.91M
EPS (ttm) 6.51
PE Ratio 31.51
Forward PE 24.07
Dividend $1.92 (0.94%)
Ex-Dividend Date May 8, 2024
Volume 108,435
Open 206.94
Previous Close 203.88
Day's Range 203.76 - 207.62
52-Week Range 132.24 - 229.97
Beta 0.66
Analysts Buy
Price Target 213.67 (+4.29%)
Earnings Date Aug 1, 2024

About RMD

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics... [Read more]

Sector Healthcare
IPO Date Jun 2, 1995
Employees 10,140
Stock Exchange NYSE
Ticker Symbol RMD
Full Company Profile

Financial Performance

In 2023, ResMed's revenue was $4.22 billion, an increase of 18.02% compared to the previous year's $3.58 billion. Earnings were $897.56 million, an increase of 15.15%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for RMD stock is "Buy." The 12-month stock price forecast is $213.67, which is an increase of 4.29% from the latest price.

Price Target
$213.67
(4.29% upside)
Analyst Consensus: Buy
Stock Forecasts

News

5 Stocks With Solid Growth History and a Promising Outlook

Five reasonably priced stocks with solid growth history and a good chance of delivering earnings even if the economy softens.

Other symbols: AWKAZOCDWWM
11 days ago - Kiplinger

ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024

SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, ...

15 days ago - GlobeNewsWire

ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn't Be.

Shares of ResMed, a maker of CPAP and other sleep-apnea airway machines, have dropped because of weight-loss developments. It's an overreaction.

21 days ago - Barrons

ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday

U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday.

Other symbols: COINNVDA
24 days ago - Benzinga

Why a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling

Shares of medical device maker ResMed (RMD) are tumbling in intraday trading Monday as markets react to a pair of Phase 3 clinical trials from drugmaker Eli Lilly (LLY) released Friday that could have...

Other symbols: LLY
24 days ago - Investopedia

Medical-device makers ResMed and Inspire slump after Lilly's Zepbound trial shows benefits for sleep apnea

Shares of medical-device makers ResMed Inc. and Inspire Medical Systems Inc. tumbled on Monday after Eli Lilly & Co. said it has applied for regulatory approval of its weight-loss drug Zepbound to inc...

Other symbols: LLY
24 days ago - Market Watch

ResMed Stock Is Sinking. Blame Lilly's Zepbound Trials for Sleep Apnea.

Eli Lilly is seeking FDA approval to expand the uses for its weight-loss drug Zepbound to include sleep apnea.

Other symbols: LLY
25 days ago - Barrons

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the ...

5 weeks ago - GlobeNewsWire

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep ...

2 months ago - GlobeNewsWire

ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When:          May 17–22, 2024 Where:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101                       Marriott Marquis...

2 months ago - GlobeNewsWire

3 Hot Stocks to Buy That Still Look Undervalued

#Morningstar  #HotStocks #StockInvesting These top-performing stocks have beaten the market in 2024 yet appear to have more room to run. 00:00 Introduction 00:43 Moderna MRNA 01:27 Hasbro HAS 02:06 Re...

Other symbols: HASMRNA
2 months ago - Morningstar

S&P 500 Gains and Losses Today: Resmed Soars Amid Strong Demand for Sleep Devices

Although the latest Personal Consumption Expenditure (PCE) data showed inflation persisting in March, strong earnings reports from several big tech firms helped major U.S. equities indexes pop higher ...

2 months ago - Investopedia

ResMed Stock Soars After Strong Earnings. Wall Street Thinks It Can Do Even Better.

The medical devices company beat expectations for its fiscal third quarter.

3 months ago - Barrons

ResMed tops quarterly profit estimates on strong demand for sleep apnea devices

ResMed beat Wall Street estimates for quarterly profit on Wednesday due to strong demand for its sleep apnea devices, sending shares 9% higher in extended trading.

3 months ago - Reuters

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com

3 months ago - GlobeNewsWire

ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, ...

3 months ago - GlobeNewsWire

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

ResMed announced the results of its 2024 Global Sleep Survey, uncovering a world in sleep crisis and encouraging people to discover their sleep superpowers

4 months ago - GlobeNewsWire

Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed's Smallest Full-Face CPAP Mask

Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask. Featuring the ...

4 months ago - GlobeNewsWire

ResMed's New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea

Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapy Part of Air11 Solutions, key features include Care Check-in, Personal Therapy Assi...

5 months ago - GlobeNewsWire

Three-Stock Lunch: SoFi, Warner Bros. Discovery and ResMed

Boris Schlossberg, BK Asset Management, joins 'Power Lunch' to discuss SoFi, Warner Bros. Discovery and ResMed.

Other symbols: SOFIWBD
6 months ago - CNBC Television

ResMed beats estimates on strong sleep apnea device sales

ResMed beat Wall Street estimates for second-quarter revenue and profit on Wednesday, powered by strong demand for its respiratory devices used to treat sleep apnea.

6 months ago - Reuters

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com

6 months ago - GlobeNewsWire

ResMed says its masks to remain on market despite FDA classification

ResMed said its respiratory masks containing magnets will remain on the market even though the U.S. Food and Drug Administration classified a recall of the product as most serious as their use could c...

6 months ago - Reuters

US FDA identifies recall of ResMed's respiratory devices as most serious

The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks made by ResMed as most serious as their use could cause major injuries or death.

6 months ago - Reuters

ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday,...

7 months ago - GlobeNewsWire